Drug Discovery & Development
MASTER technology could transform CAR T-cell therapy
A new technology that helps CAR T cells attack cancer cells more aggressively than conventional methods has been published by researchers from North Carolina. Called multifunctional alginate scaffold for T-cell engineering and release (MASTER), the technology was described in a paper published on March 24 in Nature Biotechnology. Read More
Nivolumab/chemo combo will change lung cancer care
A new study that pairs neoadjuvant nivolumab with chemotherapy for patients with nonsmall cell lung cancer has the potential to revolutionize treatment, according to one expert. The research was presented April 11 at the American Association for Cancer Research 2022 meeting and published simultaneously in the New England Journal of Medicine. Read More
CAR T-cells show preliminary efficacy, safety as solid-tumor treatment
Researchers presented phase I/II preliminary clinical trial data demonstrating the safety and efficacy of a new CAR T-cell therapy that can be used as either a monotherapy or a combination therapy to treat Claudin 6-positive solid tumors. The findings were presented at the American Association for Cancer Research Annual Meeting 2022 in New Orleans. Read More
Video from AACR 2022: Next-gen pathology tools for cancer research
NEW ORLEANS - What do the next-generation of pathology tools for cancer research look like, and how can pathologists contribute to those technologies to make an impact in their discipline? Dr. Beatrice Knudsen, PhD, of the Huntsman Cancer Institute at the University of Utah, explored these ideas at the American Association for Cancer Research (AACR) meeting in a video update from day two of the conference. Read More
Combined imaging approach gives detailed picture of blood vessels
Mapping out the intricate network of blood vessels in tissues can help researchers to better understand the changes in diseases like dementia or cancer. However, techniques to image the vasculature are individually limited and difficult to combine. Now, a new easy-to-use system, described in a paper published February 10 in the journal Nature Methods, can combine multiple imaging techniques to provide more detailed information at a range of scales. Read More
Funding for cell and gene therapies exceeded $70B in 2021
Total funding from all sources for cell and gene therapy companies totaled $70.8 billion last year, according to the recent “Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments” report published by Kalorama Information, a sister company of ScienceBoard. Read More
Scientists improve ADC development with mix of experimental, computational tools
BOSTON -- Greg Thurber, PhD, professor at the University of Michigan explained how his lab is jointly using both experimental animal models and computational models to improve the overall speed and efficiency of drug development of antibody-drug conjugates (ADCs) to get more of the agents on the market. Thurber presented in a scientific session at the Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Expo. Read More
Step toward broader treatment for Duchenne muscular dystrophy
Current therapies to treat Duchenne muscular dystrophy, a genetic muscle-wasting disease, only work in a small proportion of people with the condition. Research published on February 21 in the Proceedings of the National Academy of Science provides a proof of concept for developing a therapy that could work for almost half of the people affected. Read More
Nucleosomes dictate the histone code
The histone code concept needs to be redefined at the nucleosomal level, according to Michael-Christopher Keogh, PhD, chief scientific officer of EpiCypher. During a live webinar, Keogh shared information about the tools that are required to critically re-evaluate the genomic distribution and regulatory function(s) of histone post-translational modification (PTMs). Read More
How one company is helping make complex medicines safer
Often, the most dangerous things in life are things that the human eye cannot see. This is true even for life-saving medicines. One company was founded to help the industry find these hidden particles and solve a key challenge in the development of complex drug products. Halo Labs’ CEO Rick Gordon spoke with ScienceBoard about how its low volume approach is providing a critical service for the drug development industry. Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter